Lipid Metabolism and Tumor Antigen Presentation

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2021 Mar 19

PMID 33740250

Citations 4

Authors

Hong Qin

Yaxi Chen

Affiliations

Soon will be listed here.

Abstract

Tumors always evade immune surveillance and block T cell activation in a poorly immunogenic and immunosuppressive environment. Cancer cells and immune cells exhibit metabolic reprogramming in the tumor microenvironment (TME), which intimately links immune cell function and edits tumor immunology. In addition to glucose metabolism, amino acid and lipid metabolism also provide the materials for biological processes crucial in cancer biology and pathology. Furthermore, lipid metabolism is synergistically or negatively involved in the interactions between tumors and the microenvironment and contributes to the regulation of immune cells. Antigen processing and presentation as the initiation of adaptive immune response play a critical role in antitumor immunity. Therefore, a relationship exists between antigen-presenting cells and lipid metabolism in TME. This chapter introduces the updated understandings of lipid metabolism of tumor antigen-presenting cells and describes new directions in the manipulation of immune responses for cancer treatment.

Citing Articles

Analyzing the impact of metabolism on immune cells in tumor microenvironment to promote the development of immunotherapy.

Long Y, Shi H, He Y, Qi X Front Immunol. 2024; 14:1307228.

PMID: 38264667 PMC: 10804850. DOI: 10.3389/fimmu.2023.1307228.

The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.

Pan W, Song K, Zhang Y, Yang C, Zhang Y, Ji F Front Immunol. 2022; 13:982486.

PMID: 36119101 PMC: 9470927. DOI: 10.3389/fimmu.2022.982486.

Inhibition of UBA6 by inosine augments tumour immunogenicity and responses.

Zhang L, Jiang L, Yu L, Li Q, Tian X, He J Nat Commun. 2022; 13(1):5413.

PMID: 36109526 PMC: 9478149. DOI: 10.1038/s41467-022-33116-z.

A Novel Risk Model Based on Lipid Metabolism-Associated Genes Predicts Prognosis and Indicates Immune Microenvironment in Breast Cancer.

Ye Z, Zou S, Niu Z, Xu Z, Hu Y Front Cell Dev Biol. 2021; 9:691676.

PMID: 34195202 PMC: 8236894. DOI: 10.3389/fcell.2021.691676.

References

Shimano H, Sato R . SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017; 13(12):710-730. DOI: 10.1038/nrendo.2017.91. View

Loftus R, Finlay D . Immunometabolism: Cellular Metabolism Turns Immune Regulator. J Biol Chem. 2015; 291(1):1-10. PMC: 4697146. DOI: 10.1074/jbc.R115.693903. View

De Libero G . Editorial overview: Antigen processing. Curr Opin Immunol. 2018; 52:iv-v. DOI: 10.1016/j.coi.2018.05.016. View

Lees J . Targeting antigen presentation in autoimmunity. Cell Immunol. 2018; 339:4-9. DOI: 10.1016/j.cellimm.2018.12.006. View

Kotsias F, Cebrian I, Alloatti A . Antigen processing and presentation. Int Rev Cell Mol Biol. 2019; 348:69-121. DOI: 10.1016/bs.ircmb.2019.07.005. View

Jensen P . Recent advances in antigen processing and presentation. Nat Immunol. 2007; 8(10):1041-8. DOI: 10.1038/ni1516. View

van den Elsen P . Expression regulation of major histocompatibility complex class I and class II encoding genes. Front Immunol. 2012; 2:48. PMC: 3342053. DOI: 10.3389/fimmu.2011.00048. View

Burgdorf S, Kurts C . Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol. 2008; 20(1):89-95. DOI: 10.1016/j.coi.2007.12.002. View

Joffre O, Segura E, Savina A, Amigorena S . Cross-presentation by dendritic cells. Nat Rev Immunol. 2012; 12(8):557-69. DOI: 10.1038/nri3254. View

10.

Bevan M . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976; 143(5):1283-8. PMC: 2190184. DOI: 10.1084/jem.143.5.1283. View

11.

Bevan M . Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol. 1976; 117(6):2233-8. View

12.

Sanchez-Paulete A, Teijeira A, Cueto F, Garasa S, Perez-Gracia J, Sanchez-Arraez A . Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017; 28(suppl_12):xii44-xii55. DOI: 10.1093/annonc/mdx237. View

13.

Sabado R, Balan S, Bhardwaj N . Dendritic cell-based immunotherapy. Cell Res. 2016; 27(1):74-95. PMC: 5223236. DOI: 10.1038/cr.2016.157. View

14.

Moody D, Cotton R . Four pathways of CD1 antigen presentation to T cells. Curr Opin Immunol. 2017; 46:127-133. PMC: 5599164. DOI: 10.1016/j.coi.2017.07.013. View

15.

Mildner A, Jung S . Development and function of dendritic cell subsets. Immunity. 2014; 40(5):642-56. DOI: 10.1016/j.immuni.2014.04.016. View

16.

Guilliams M, Ginhoux F, Jakubzick C, Naik S, Onai N, Schraml B . Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014; 14(8):571-8. PMC: 4638219. DOI: 10.1038/nri3712. View

17.

Patente T, Pinho M, Oliveira A, Evangelista G, Bergami-Santos P, Barbuto J . Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front Immunol. 2019; 9:3176. PMC: 6348254. DOI: 10.3389/fimmu.2018.03176. View

18.

Roberts E, Broz M, Binnewies M, Headley M, Nelson A, Wolf D . Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016; 30(2):324-336. PMC: 5374862. DOI: 10.1016/j.ccell.2016.06.003. View

19.

Houston S, Cerovic V, Thomson C, Brewer J, Mowat A, Milling S . The lymph nodes draining the small intestine and colon are anatomically separate and immunologically distinct. Mucosal Immunol. 2015; 9(2):468-78. DOI: 10.1038/mi.2015.77. View

20.

Crispe I . Liver antigen-presenting cells. J Hepatol. 2010; 54(2):357-65. PMC: 3031082. DOI: 10.1016/j.jhep.2010.10.005. View